ProCE Banner Activity

Phase Ib Study of Venetoclax With Decitabine or Azacitidine in Elderly Patients With Untreated Acute Myeloid Leukemia

Slideset Download
Conference Coverage
Preliminary findings suggest venetoclax plus decitabine or azacitidine is well tolerated with deep, durable responses in elderly patients with previously untreated AML.

Released: June 07, 2018

Expiration: June 06, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen